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Introduction
Fever is the most common indicator of disease in human malaria, but the mechanisms for its induction and regulation during the disease is not clear. From studies with the bacterial product LPS, it has for many years 0001-706X/$ -see front matter © 2006 Elsevier B.V. All rights reserved. doi: 10.1016/j.actatropica.2006.07.005 been thought that fever is induced via the intermediate production of pyrogenic cytokines (IL-1, TNF-␣, IL-6, IL-8, MIP-1␤, and IFN-␥) and that the height and magnitude of fever is a sum of the interactions of pyrogenic cytokines and endogenous antipyretics (IL-10, AVP and glucocorticoids) (Leon, 2002) . However, the concept is challenged by findings indicating that fever during infection can occur independently of cytokine production (Dinarello, 2004) . Toll-like receptor (TLR) signal transduction provides an explanation by which microbial products can cause fever directly on the vascular network supplying the thermoregulatory centre in the anterior hypothalamus. Thus, fever during an infection is now thought to be a result of both cytokine and TLRs (or other receptors) ligand activity, followed by cyclooxygenase-2, prostaglandin E 2 (PGE 2 ) production and activation of hypothalamic PGE 2 receptors.
There are several relations that indicate a pivotal role for pro-inflammatory cytokines in induction of malarial fever. Malaria parasite derived glycosylphosphatidylinositol (GPI) induces TNF and IL-1 in macrophages and causes pyrexia in mice models (Schofield and Hackett, 1993) . Elevated plasma levels of TNF, IL-6 and IFN-␥ are detected during uncomplicated Plasmodium falciparum malaria compared to asymptomatic infections (Mshana et al., 1991; Anstey et al., 1996; Othoro et al., 1999) . For the cytokines IL-1␤, IL-4, IL-12, IL-13 and IL-18 the information is less clear, or so far missing (Mshana et al., 1991; Othoro et al., 1999; Chaisavaneeyakorn et al., 2003) . Plasmodium vivax fever episodes appear with 48 h intervals coinciding with increased serum levels of TNF (Karunaweera et al., 1992) . In human cerebral malaria, fever was reduced by injection of anti-TNF antibodies (Kwiatkowski et al., 1993) . This does however not exclude the possibility that at least a part of the fever induction in non-complicated P. falciparum malaria is cytokine independent.
We have previously shown that the antimalarial drug chloroquine exerts antipyretic effects, equal to paracetamol, during treatment of uncomplicated P. falciparum malaria (Hugosson et al., 2003) . Chloroquine inhibits production of several pro-inflammatory cytokines and enhances IL-10 production in human in vitro assays (Hugosson et al., 2002; Picot et al., 1993; Ertel et al., 1991; Landewe et al., 1992; van den Borne et al., 1997; Karres et al., 1998; Jeong and Jue, 1997) . The protection of rats challenged by lethal doses of CpG and LPS by chloroquine treatment is associated with decreases in serum levels of TNF-␣ and IL-6 (Hong et al., 2004) . It is therefore reasonable to believe that chloroquine could inhibit malarial fever by altering the levels and the balance of the cytokine response during malaria infections.
However, recent evidence suggests that chloroquine can block signalling via TLRs Zou et al., 2003) , which provides a possible mechanism for a cytokine independent mechanism for the antipyretic activity of chloroquine.
In order to study the role of pro-and anti-inflammatory cytokines in relation to fever and in chloroquine induced antipyresis, we compared cytokine levels before and during treatment of acute uncomplicated P. falciparum malaria. We investigated differences between four drug regimes generating different effects on the body temperature.
Methods

Study area
The study was carried out in Kibaha District Hospital 40 km north-west of Dar es Salaam, Tanzania, an area holoendemic for malaria with largely perennial transmission of mainly P. falciparum.
Study patients
Data and samples in this work are obtained from patients included in a study designed to compare antipyretic, parasitological and immunulogical effects of four different antimalarial treatment regimes (Hugosson et al., 2003) . Children between 12 and 59 months of age attending the primary health care unit of the hospital, between 3 July and 20 August 1998, were included in the study, if they fulfilled the inclusion criteria of uncomplicated mono-infection with P. falciparum (2000-250 000 parasites/mL, axillary temperature 37.5-40.0 • C). Children were not considered for the study if they had altered level of consciousness, convulsions, prostration, circulatory shock or respiratory distress, hyperparasitemia (>250 000 parasites/L), severe anaemia (haemoglobin levels below 5.0 g/dL) or suspected coexisting diseases. The guardians of the children, were asked for their informed consent before the children were enrolled in the study. Ethical clearance was provided by the Ministry of Health, Tanzania and by clinical research committee of the Karolinska Institutet, Stockholm, Sweden. A more detailed information about the patients is provided in a previous report (Hugosson et al., 2003) .
Drug administration
At admission to the hospital, the patients were consecutively divided into either of four treatment groups, according to a predetermined schedule: (1) chloroquine alone, (2) sulfadoxine/pyrimethamine (SP) alone, (3) SP + chloroquine, and (4) SP + paracetamol. The three drugs were given as follows: (a) chloroquine phosphate (F Hoffman-La Roche, Basel, Switzerland) 10 + 10 + 5 mg base/kg body weight (BW) over a period of 3 days, (b) SP (Fansidar ® , F HoffmanLa Roche, Basel, Switzerland) single dose of 1.25 mg pyrimethamine and 25 mg sulfadoxine/kg BW, and (c) paracetamol, 15 mg/kg BW every 8 for 72 h. All treatments started at 3-4 p.m. on the day of admission and were given under close supervision by the research team. No antipyretic drugs were given to the children apart from the treatment schedule defined above. Mechanical antipyresis (tepid sponging and electric fanning) was to be considered during episodes of high fever (>39 • C).
Sample collection and microscopy
Venous blood samples were taken on day 0 (before start of treatment) (=T 0 ) and on day 2 (=T 2 ) and 3 (=T 3 ), respectively. After centrifugation, the plasma was immediately aliquoted and stored at −30 • C during the time of the study (at the most 2 months) and thereafter at −70 • C until transferred on dry ice before being finally stored at −70 • C until analysed year 2000. Axillary body temperature was measured at attendance to the primary health care unit to the hospital, at start of treatment (T 0 ) and then every 6 up to 72 h. Parasite species was assessed in Giemsa-stained thin blood smears at admission. Parasite densities were estimated, in thick smears, by counting asexual parasites per 200 leucocytes. This was performed before admission and every 24 up to 72 h. Out of 169 patients who participated in the study until 72 h, samples from 104 patients, equally distributed between the four treatment groups (21 in each group), were randomly selected for cytokine analyses.
Antibodies used for cytokine determination
The following mouse antibodies against human cytokines were used as catcher antibodies: IL-4 (82.4), IL-6 (13A5), IL-10 (9D7), IL-12-I (p40 chain), IL-13-I, IFN-␥ (1DIK) (MABTECH, Stockholm, Sweden), IL-1␤ (ILB1-H6) (Endogen, Woburn, MA, USA) and TNF-␣ (Mab1) (Pharmingen, San Diego, CA, USA). Biotinylated antibodies used for detection were: IL-4 (12.1), IL-6 (39C3), IL-10 (12G8), IL-12-II (p40 chain), IL-13-II, IFN-␥ (7-B6-1) (MABTECH, Stockholm, Sweden), IL-1␤ (ILB1-H67) (Endogen, Woburn, MA, USA) and TNF-␣ (Mab11) (Pharmingen). Goat antibodies against human IL-18 (52713.11 and BAF 318) were purchased from R&D systems (Abingdon, United Kingdom). Blocking antibodies were: mouse Ig (1DIK or 9D7) (MABTECH, Stockholm, Sweden) or normal goat IgG (AB-108-C).
Cytokine determinations
The cytokines were analysed by sandwich ELISAs. Briefly, half-area ELISA plates (Corning Incorporated, Corning, NY, USA) were coated over night at 4 • C with 25 L of catcher antibodies (1 g/mL). Phosphate buffered saline (PBS) supplemented with 0.05% Bovine serum albumin was used for blocking (90 min, at RT) and for dilution of standards and samples. To reassure specific binding, blocking antibodies were applied to the plates immediately before addition of the samples and standards. All test samples were coded and applied randomly in duplicates (diluted 1:1) into the pre-coated plates and incubated over night at 4 • C. Bound cytokines were assayed using biotinylated cytokine specific antibodies (for 2 h, at 37 • C), followed by alkaline phosphatase (ALP)-conjugated streptavidin (MABTECH, Stockholm, Sweden) diluted 1:1000 and incubated (90 min, at RT). Thereafter the phosphatase substrate (Sigma Diagnostics, St. Louis, MO, USA) was applied and the optical density was read at 450 nm. Cytokine concentrations were calculated from standard curves obtained by incubating serial dilutions of the respective recombinant cytokines (NIBSC, Hertfordshire, United Kingdom or IL-18 from R&D systems, Abingdon, United Kingdom). Standards were aliquoted and stored at −70 • C. The detection limits were set according to the linear part of the standard curve and the background values of buffer controls and were for: IL-1␤ 3-3000, IL-4 10-3000, IL-6 30-10 000, IL-10 30-3000, IL-12 10-3000, IL-13 15-2000, IL-18 100-30 000, TNF-␣ 30-4000 pg/mL and IFN-␥ 0.01-30 U/mL, respectively.
Calculations and statistics analysis
All correlations were analysed with the non-parametric Spearman rank order coefficient. In case of nondetectable levels a value of 1 (or 0.01 for IFN-␥) was used. Ratios were calculated by dividing the cytokine levels of two different cytokines. Comparison of plasma cytokine levels between treatment groups was analysed by Kruskal Wallis test for ranked median values. Comparisons between the cytokine levels at different time points were analysed by Friedman ANOVA and the post hoc test by Wilcoxon. Progression of cytokine responses in the different treatment groups was calculated by subtracting the values (plasma levels or ratios) at the second time point from the first and the differences between the treatment groups were compared by Kruskal Wallis test for ranked median values. Ratios in the different treatment groups at different time points were compared by Kruskal Wallis test for ranked medians. All statistical tests were two sided with a significance level of p < 0.05. The Bonferroni correction is sometimes used when testing multiple variables, since the more associations that are studied, the greater likelihood of finding one that exists solely due to chance. A higher threshold for statistical significance is calculated by dividing the current threshold (p = 0.05) by the number of cytokines tested ((p = 0.05)/9), which gives (p = 0.006). The significance of this correction is disputed in some circumstances, but is included in the result part as a complement (Perneger, 1998) .
Results
Relationships between fever, parasitemia and plasma levels of cytokines
Pre-treatment plasma levels and the frequencies of detection of the nine cytokines tested are presented in Table 1 . Associations between cytokine levels, parasitemias and body temperatures are presented in Table 2 . Because of the fluctuations of the temperature over time, a mean value was calculated from the measurement before admittance and from that of start of treatment. Strongest associations were found between body temperature and IL-10, IFN-␥ and IL-6 (Table 2 ). Significant associations were also detected between parasitemia at day 0 and plasma levels of IL-6 and IL-10 (Table 2) . On day 2, IL-10 and IL-6 levels still correlated with body temperature and IL-10 levels with parasitemia (Table 2) . Spearman rank order correlations (n = 104).
If the Bonferroni correction is used for multiple variable testing this would change the threshold for statistical significance to p = 0.006, which would render the association between temperature and IFN-␥ to borderlineand temperature-IL-6 and parasitemia-IL-10 day 0 below statistical significance. However, the likelihood of false positive results because of multiple variable testing is low, since there is a statistical significant association between temperature and IL-6 and parasitemia and IL-10, respectively, at both day 0 and day 2.
Effects of antimalarial treatment on plasma cytokine levels
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cytokine levels with time, or in the number of individuals with increasing/decreasing plasma levels between the time points were detected. A "balance" between pro-inflammatory and anti-inflammatory cytokines is thought to determine the outcome of disease. Ratios between the different cytokines did not differ between the treatment groups at any of the time points tested (not listed). Nor did changes in ratio values between the time points differ between the treatment groups (not listed).
Kinetics of cytokine levels in plasma during treatment
Data from all individuals were pooled for the kinetic analysis, since no differences were seen in cytokine levels between the treatment groups. From the start of the treatment (T 0 ), the median levels of all tested cytokines, decreased significantly (p < 0.05, ANOVA for repeated measure, Wilcoxon) up to day 2, except for TNF-␣ and IL-1␤ for which no significant effect was found (Fig. 1) . IL-6 continued to fall from days 2 to 3 (p < 0.05) while IL-12, IL-13, IL-18 and IL-1␤ all increased (p < 0.05). Statistically significant net decreases in plasma levels from days 0 to 3 were seen for IFN-␥, IL-10, IL-6 and IL-4. 
Discussion
We hypothesised that chloroquine decreases fever and exhibit its anti-inflammatory effects by altering the levels and the balance of cytokine responses during malaria infections. However, despite significant associations between fever and plasma levels of several cytokines and clear antipyretic effects of chloroquine and paracetamol, no differences were detected in cytokine levels or ratios compared to those treated without antipyretics. The method of measuring of body temperature used here is somewhat imprecise. The result of this imprecision is that any associations with cytokine levels will be estimated conservatively. This form of variation around the 'true' temperature is not differential and cannot create a spurious association. The associations we report are therefore unlikely to be artefacts created due to imprecise temperature measurement. However, such imprecision may mask associations or will certainly reduce the statistical significance of true associations. Because we see corresponding associations at different time points between cytokine levels and temperature and parasitemia, respectively, we believe that it is unlikely that any of the associations listed appear solely by chance.
We found that before start of treatment, fever was positively associated with plasma levels of IL-10, IL-6 and IFN-␥. A positive association between fever and IFN-␥ has been determined in patients with P. vivax malaria (Brown et al., 1991; Seoh et al., 2003) . IFN-␥ is not known to have direct pyretic effects but may contribute to fever via stimulation of IL-1␤ and TNF production in macrophages (Dinarello, 1999) . IL-6 is best known for its systemic action on the liver, causing production of acute phase proteins and is also necessary for promoting the fever induced by TNF and IL-1, cytokines known to enhance the IL-6 production (Zetterstrom et al., 1998) . The body temperature did, however not, correlate with TNF-␣ nor IL-1␤, which suggests that IFN-␥ and IL-6 might be connected with fever independently of these cytokines in our patients.
In contrast to our findings, TNF-␣ levels have been shown to correlate with fever in several other studies (Grau et al., 1989; Mordmuller et al., 1997; Kwiatkowski et al., 1993; Karunaweera et al., 1992) . The reason for this discrepancy may be that we studied children with uncomplicated P. falciparum malaria only, while others have included patients with severe disease or P. vivax. Stronger associations between fever and TNF in severe P. falciparum may result from generally higher and less fluctuating levels. Additionally, the severe disease manifestations might in turn contribute to the fever, thus amplifying the association.
The positive association between the IL-6 levels and parasitemia, indicates that the parasites perhaps could promote fever via induction of IL-6. The lack of correlation between IFN-␥ and parasitemia suggests that other factors than the parasite load are of importance for the production of IFN-␥ and for its association with fever. The importance of the host's degree of immunity for the production of IFN-␥ has been implied in in vitro studies using PBMC from individuals living in areas of different malaria endemicity (Rhee et al., 2001; Migot-Nabias et al., 1999) . Thus, while there could be a causal relationship between parasite load and fever via the production of IL-6, the relationship between parasite load and fever with IFN-␥ seems more complex.
IL-10 is known to down regulate the production of pro-inflammatory cytokines like IL-1␤, TNF-␣, IL-6 and IL-12 (Moore et al., 2001) and to act as an endogenous antipyretic by lowering LPS-induced fever in mice (Leon et al., 1999) . However, the positive correlation between body temperature and IL-10, IFN-␥ and IL-6 in our study suggests a poor antipyretic effect or a limited ability of IL-10 to balance the production of these cytokines during malaria infection. Earlier studies show that production of higher levels of IL-10 is associated with less effective clearance of P. falciparum parasites (Hugosson et al., 2004; Jakobsen et al., 1996) . It is also possible that IL-10 hinders the host's ability to clear parasites by suppressing antigen presentation and/or enhancing activation of regulatory T or B cells. The kinetics of the cytokine production in the present study revealed that the production of several cytokines, especially IL-1␤ and IL-12, increased in levels between days 2 and 3 of treatment. The reason for this is unknown but could perhaps be a consequence of a diminished suppressive effect by IL-10 when the levels of this cytokine decrease.
The fact that the cytokines that correlated with fever also decreased during treatment suggests that their subsequent production may somehow be related to the induction or the maintenance of the fever. However, the association could alternatively be explained by a common or parallel induction pathway for fever and pro-inflammatory cytokines. We have previously shown that lower mean temperatures (6-48 h) are achieved with SP + chloroquine and SP + paracetamol compared to SP alone or chloroquine alone (Hugosson et al., 2003) . In this study we show that these differences were not reflected by differences in levels of any of the nine cytokines. The antipyretic effect of chloroquine was evident already after 6 h (Hugosson et al., 2003) . A close kinetic study within that time interval might reveal if the antipyretic effect is connected with early changes in endopyrogenic cytokine levels or their downstream mediators. However, the slow decrease in body temperature in the group treated with SP alone indicates that whatever induces the fever, continues to do so even when the parasite mass is considerably reduced. The antipyretic effect of chloroquine therefore seems to be long lasting and thus potential chloroquine induced changes in cytokine levels should be expected to be seen also at later time points. The lack of differences in cytokine levels between the treatment groups could depend on too large individual differences among the patients in regard to genetics, maturity of the immune system, age, previous exposure to malaria, and other disease related differences. Another interpretation of the results is that chloroquine exerts its antipyretic effect at another level than on the production of the cytokines. Treatment with SP + paracetamol did not change the cytokine levels compared to SP alone. This is in line with that paracetamol is thought to suppresses the production of PGE 2 by a mechanism downstream to cytokine production (Graham and Scott, 2005) . Similar effects could be true for chloroquine.
It has recently been shown that chloroquine can inhibit signalling through TLRs Zou et al., 2003) . The vast product of malaria parasites, haemozoin, was shown to induce pro-inflammatory responses in dendritic cells via signalling through TLR9 (Coban et al., 2005) . The inhibiting effect of chloroquine is specific for some TLRs and their differential distribution might explain the different effects of chloroquine on different cell types Park et al., 2003) . Chloroquine might therefore directly inhibit cytokine independent fever induction via TLRs (or other receptors) in the brain, while having no short turn effect on the plasma cytokine levels in uncomplicated P. falciparum malaria. Whether chloroquine's inhibiting effect on signalling pathways for TLRs has a clinical impact during human malaria infections still remains to be elucidated.
In conclusion, our data show associations between fever and plasma levels of IFN-␥, IL-10 and IL-6, while the antipyretic effects of chloroquine could not be explained by changes in production of these cytokines. However, further studies are needed to determine at what level in the inflammatory process chloroquine exerts its main anti-inflammatory and antipyretic effects.
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